Skip to content

Funding Announcements

Filter

Filter & sort

Keyword

Tag

Round

Sort by

Clear

The latest funding rounds from the UK tech ecosystem. Updated 16 October 2026.

Announcements

308

Total raised

£4.1B

disclosed amounts

This month

£27.8M

raised so far

$6.0M

The London-based clinical trials platform has secured $6m to date from high-profile investors.

"Clinical trials are the biggest bottleneck to improving human health. We’re working with high-growth companies developing the next wave of breakthrough treatments to accelerate the clinical trials process."
— Michael Young, Co-Founder
£1.5M

The funding round was led by the Development Bank of Wales to advance first-in-human studies.

"Vaccination and treatments have reduced the impact of the virus but it is still a significant health risk. Our self-administered and cost-effective antiviral treatment stops the virus from entering and multiplying in the nasal epithelial cells, where it can then spread to the throat and then into the lungs. It is a potential game-changer in the treatment and prevention of coronaviruses, particularly with the emergence of new viruses."
— Imre Berger, Professor
Seed
£6.0M

MP Healthcare led the pre-Series A financing to help fund the expansion of the company drug discovery pipeline in oncology and neurology.

"At PharmEnable, we believe that everyone deserves safe and effective treatments, and we are committed to applying the principles chemical novelty, diversity and 3-dimensionality to design powerful new small molecule drugs."
— Hannah Sore, CEO
Grant
£490K

The biotechnology startup received the grant to scale up manufacturing processes for green cosmetic compounds.

"This collaboration with Teesside University, led by Associate Professor Dr. M. Safwan Akram an expert in Synthetic biology and BiBerChem Research led by Professor Bernard Golding a Synthetic Organic Chemist brings together our complementary strengths and expertise, and we are excited to see the results of our joint efforts in this important area"
— Olusola Idowu, CEO